يعرض 2,041 - 2,060 نتائج من 6,596 نتيجة بحث عن '(( significant decrease decrease ) OR ( significant changes decrease ))~', وقت الاستعلام: 0.37s تنقيح النتائج
  1. 2041
  2. 2042
  3. 2043

    Supplementary Figs 1–7. حسب Juliane F. Tampé (19976538)

    منشور في 2024
    الموضوعات:
  4. 2044

    Supplementary Tables 1–8. حسب Juliane F. Tampé (19976538)

    منشور في 2024
    الموضوعات:
  5. 2045
  6. 2046
  7. 2047
  8. 2048
  9. 2049

    Mass spectrometric analyses for crystallins. حسب Akosua K. Boateng (21672931)

    منشور في 2025
    "…Previous <i>in-vitro</i> studies of recombinant βA3ΔG91 showed defective folding, decreased solubility, and aberrant oligomerization of βA3ΔG91 with other crystallins. …"
  10. 2050

    RNA-seq data showing top 15 downregulated genes. حسب Akosua K. Boateng (21672931)

    منشور في 2025
    "…Previous <i>in-vitro</i> studies of recombinant βA3ΔG91 showed defective folding, decreased solubility, and aberrant oligomerization of βA3ΔG91 with other crystallins. …"
  11. 2051

    RNA-seq data showing top 15 upregulated genes. حسب Akosua K. Boateng (21672931)

    منشور في 2025
    "…Previous <i>in-vitro</i> studies of recombinant βA3ΔG91 showed defective folding, decreased solubility, and aberrant oligomerization of βA3ΔG91 with other crystallins. …"
  12. 2052

    Study flow chart. حسب Raymond Atwine (18574812)

    منشور في 2025
    "…The risk of ADCs increased from stage 2 (OR: 0.46, p-value: 0.03; 95% CI: 0.23–0.91) to stage 3 (OR: 1.13; p-value: 0.66; 95% CI: 0.65–1.97) but this was not statistically significant. The risk of ADCs decreased with increasing ART duration (<i>P</i> value < 0.05).…"
  13. 2053

    Bar graph showing proportion of NADCs. حسب Raymond Atwine (18574812)

    منشور في 2025
    "…The risk of ADCs increased from stage 2 (OR: 0.46, p-value: 0.03; 95% CI: 0.23–0.91) to stage 3 (OR: 1.13; p-value: 0.66; 95% CI: 0.65–1.97) but this was not statistically significant. The risk of ADCs decreased with increasing ART duration (<i>P</i> value < 0.05).…"
  14. 2054

    Baseline characteristics of study participants. حسب Raymond Atwine (18574812)

    منشور في 2025
    "…The risk of ADCs increased from stage 2 (OR: 0.46, p-value: 0.03; 95% CI: 0.23–0.91) to stage 3 (OR: 1.13; p-value: 0.66; 95% CI: 0.65–1.97) but this was not statistically significant. The risk of ADCs decreased with increasing ART duration (<i>P</i> value < 0.05).…"
  15. 2055
  16. 2056
  17. 2057
  18. 2058
  19. 2059
  20. 2060